Navigation Links
NPS Pharmaceuticals Announces Results of Tender Offer
Date:10/18/2007

al development. Additional information is available on the company's website, http://www.npsp.com.

This press release contains forward-looking statements intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to strategies, expectations, intentions, plans, future events, performance, underlying assumptions, and other statements that do not relate strictly to historical or current facts. Although NPS Pharmaceuticals' management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. These statements can be affected by inaccurate assumptions and by a variety of risks and uncertainties, including, among others, general economic conditions, the success of the tender offer for the 3.0% Convertible Notes due 2008 and the amount of any such notes actually tendered for repurchase or actually repurchased by the company, the company's reported results meeting the company's guidance and the expectations of the market, and other risks, including risks related to NPS Pharmaceuticals' operations and financial condition, detailed in NPS Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2006, NPS Pharmaceuticals' Quarterly Reports on Form 10-Q for the quarters ended March 31, 2007 and June 30, 2007 and any other reports of the company filed with the Securities and Exchange Commission. Should one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. NPS Pharmaceuticals does not undertake a
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/26/2015)... 2015 Ale Gicqueau, Founder and President ... Clinical Affairs at Align Technology, on “ Conducting Postmarket ... ACRP 2015 Global Conference and Exhibition on April 25th ... , During the poster presentation, Ale Gicqueau and Victor ... a Postmarket Registry, the requirements and resources to conduct ...
(Date:3/25/2015)... is one of the most attractive in the emerging ... a growing economy and increasing government investment in healthcare, ... Russian market is set to grow at twice the ... around 10-15% annually reaching an approximate market value of ... Green Cross provides total healthcare solutions that ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /PRNewswire/ - SQI Diagnostics ... announced that, as a result of recent discussions with ... common shares of the Company, after dealing with certain ... and special meeting of shareholders on March 26, 2015 ... that the election of directors will take place when ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
... Reportlinker.com announces that a new market research report ... Global Genetic Engineering Industry ... The global outlook series on Genetic ... concise summaries of research findings. The report offers ...
... SGMO ) today announced that the company will ... 2, 2012, after the market closes. The press release will ... which will be open to the public via telephone and ... financial results and discuss other business matters. The ...
... Diagnostic Laboratory announced today that it has entered ... ancillary diagnostics laboratory testing. The agreement includes Aviir,s ... Networks. Aviir was founded in 2005 ... School of Medicine to focus on discovery, development ...
Cached Biology Technology:Global Genetic Engineering Industry 2Global Genetic Engineering Industry 3Global Genetic Engineering Industry 4Global Genetic Engineering Industry 5Global Genetic Engineering Industry 6Global Genetic Engineering Industry 7Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2Aviir Laboratories Announce National Agreement With MultiPlan 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... MasterLock(R) smartTOUCH(TM) ... Leading Product in Lab Testing, JERICHO, N.Y., June 4 ... personal identification based,consumer products, today announced that the MasterLock(R) smartTOUCH(TM),GDO ... was,named best in class and the most reliable biometric garage ...
... University professor has developed a new water treatment that ... Lake Superior. David Hand, a professor of civil ... simple way to treat ballast water in vessels ranging ... designed to kill the virus that causes viral hemorrhagic ...
... This release is available in Spanish . , ... Virgen de las Nieves Hospital have found out ... consequently, their clinical situation by taking a simple exogenous antioxidant ... stress increase during patients stays in the Intensive Care Unit ...
Cached Biology News:bioMETRX, Inc. Garage Door Opener Named 'Best In Class' 2New ballast treatment could protect Great Lakes fish 2A nutritional supplement could improve the clinical situation of ICU patients 2
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
...
Biology Products: